{"url_path":"/sec/ganx/8-k/2026-06-25/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 ****Submission of Matters to a Vote of Security Holders**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-077820-index.html","accession_number":"0001104659-26-077820","cik":"0001819411","ticker":"GANX","issuer_name":"Gain Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819411/0001104659-26-077820-index.html","primary_entity_key":"0001819411","primary_entity_name":"Gain Therapeutics, Inc."},"word_count":272,"has_tables":true,"body_markdown":"**Item 5.07****Submission of Matters to a Vote of Security Holders**\n\n \n\nOn June 24, 2026, Gain Therapeutics, Inc. (the\n“Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which a quorum was present. The\nmatters voted on at the Annual Meeting were: (1) the election of seven directors, and (2) the ratification of the appointment of Ernst\n& Young AG as the Company’s independent registered public accounting firm. The final voting results were as follows:\n\n \n\n1. The election of Gene Mack, Dov Goldstein, M.D.,\nHans Peter Hasler, Khalid Islam, Ph.D., Gwen Melincoff, Claude Nicaise, M.D., and Jeffrey Riley as directors to hold office for a term\nof one year, until their successors are duly elected and qualified or they are otherwise unable to complete their respective terms. The\nvotes were cast for this matter were as follows:\n\n \n\nNominee \nFor  \nWithheld  \nBroker Non-Vote \n\nGene Mack \n 13,618,503  \n 1,691,620  \n 11,670,126 \n\nDov Goldstein, M.D. \n 14,477,046  \n 833,077  \n 11,670,126 \n\nHans Peter Hasler \n 13,517,744  \n 1,792,379  \n 11,670,126 \n\nKhalid Islam, Ph.D. \n 14,393,372  \n 916,751  \n 11,670,126 \n\nGwen Melincoff \n 14,459,942  \n 850,181  \n 11,670,126 \n\nClaude Nicaise, M.D. \n 14,472,350  \n 837,773  \n 11,670,126 \n\nJeffrey Riley \n 14,148,296  \n 1,161,827  \n 11,670,126 \n\n \n\n2. The proposal to ratify the appointment of Ernst\n& Young AG as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved\nbased upon the following votes:\n\n \n\nFor \nAgainst \nAbstain\n\n25,865,468 \n1,074,319 \n40,462\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**GAIN THERAPEUTICS, INC.**\n\n \n \n\nDate: June 25, 2026\nBy:\n*/s/ Gene Mack*\n\n \nName:\nGene Mack\n\n \nTitle:\nChief Executive Officer"}